Recent News

• 02.27.2025 - Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
• 02.20.2025 - Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
• 01.29.2025 - Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
• 11.26.2024 - Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
• 11.13.2024 - Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
• 11.07.2024 - Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
• 11.07.2024 - Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
• 10.28.2024 - Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
• 10.24.2024 - Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
• 10.24.2024 - Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Recent Filings